Bristol Myers Squibb is transferring five immunology assets, including three clinical-stage drugs, to a new biotech company backed by $300 million in funding from Bain Capital. This move demonstrates the pharmaceutical giant’s shift towards strategic partnerships and asset sales in the growing immunology sector.
Source: https://endpoints.news/bristol-myers-sends-five-immunology-assets-to-new-300m-biotech